ERBB2 and breast carcinoma: At the lowest administered concentration (0.01 mg mL−1), the conjugated antibodies significantly enhanced the NPs' cellular uptake in HER2-overexpressing BT-474 breast cancer cells, and a synergistic effect between the SLN and CAB51 was observed.